Tscan therapeutics announces exercise of underwriters' option to purchase additional shares

Waltham, mass., april 24, 2024 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr)-engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced that the underwriters of its previously announced public offering, which closed on april 19, 2024, have partially exercised their over-allotment option to purchase an additional 2,485,487 shares of its voting common stock at the public offering price of $7.13 per share, less underwriting discounts and commissions. after giving effect to the option closing, the total number of shares sold by the company in the offering were 4,958,068 shares, which along with pre-funded warrants to purchase up to an aggregate of 18,577,419 shares of its voting common stock, resulted in aggregate gross proceeds to the company of approximately $167.8 million before deducting underwriting discounts and commissions and estimated offering expenses payable by the company.
TCRX Ratings Summary
TCRX Quant Ranking